Among several, the lung cancer is the most common and lethal tumor in the worldwide. Wide- variety of drugs are available for the treatment of the disease. However, strong side effects and innate or gained resistance of tumor cells to existing agents leads researchers to develop alternative agents with more effective and less side effects. Anthraquinone-derived drugs such as doxorubicin, mitoxantrone, epirubicin, idarubicin, and valrubicin are currently used to cure various of cancers. In this concept, novel 2-aminoanthraquinone substituted cyclotriphosphazene compounds 5–7 have been synthesized by our group and have been fully characterized by means of FT-IR, MALDI-TOF MS, 1H- and 31P NMR spectroscopies.Furthermore, anti-carcinogenic potential of the compounds was investigated on non-small-cell Lung Carcinoma (NSCLC) cell lines and as well as non-tumoral mesothelial cells (MeT-5A). Results showed that compared to others, the most effective compound to reduce the viability of cancer cells and to induce apoptosis was compound 7. Significantly, compound 7 has showed selectivity to cancer cells rather than its normal counterpart.